Cancer prevention and/or treatment may be possible by using statins as mevalonate pathway inhibitors through their ability to degrade mutant-p53 (Cerqueira et al., 2016; Iannelli et al., 2018), and interactions with essential cellular functions, such as cell proliferation and differentiation (Hissa and Pontes, 2018). Here, TP53 is linked to cancer.